The conservation and characterization of preservation fluids are crucial for maintaining specimen integrity in natural history fluid collections. However, characterizing these fluids analytically poses significant challenges, especially as noninvasive methods are preferred to avoid opening jars and reduce the risk of compromising specimens. This proof-of-concept study investigates the feasibility of using a hand-held spatially offset Raman spectroscopy (SORS) instrument to determine the chemical composition of preservation fluids through their original glass containers. Results demonstrate that SORS can noninvasively verify the chemical identity of dominant excipients in these fluids measured through a historic glass jar. Additionally, multivariate analysis combined with SORS measurements successfully differentiated several types of typical preservation fluids prepared as mixtures of different alcohols in water, such as glycerol, ethanol, methanol, and formaldehyde. The proposed noninvasive approach was also able to differentiate between different concentration points of components in water within the same type of preservation fluid.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886732 | PMC |
| http://dx.doi.org/10.1021/acsomega.4c11521 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of pulmonary toxicity of inhaled polycarbonate 3D printer emissions in rats.
J Toxicol Environ Health A
March 2025
Pathology and Physiology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV, USA.
This study investigated the potential pulmonary toxicity of polycarbonate (PC) emissions from fused filament fabrication (FFF) three-dimensional printing (3DP) via inhalation in Sprague Dawley rats. Previously, our results demonstrated no significant pulmonary effects following exposure to a 0.5 mg/m PC.
View Article and Find Full Text PDFCase Report: A modified approach to converting ventriculoperitoneal shunt to ventriculoatrial shunt due to recurrent encapsulation of the peritoneal catheter.
Front Surg
February 2025
Department of Neurosurgery, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
Background: Hydrocephalus is a condition characterized by the accumulation of cerebrospinal fluid (CSF) in the ventricular system due to various causes, including excessive CSF production, impaired circulation, or absorption dysfunction. This condition is often accompanied by ventricular enlargement, compression of brain parenchyma, and increased intracranial pressure. Ventriculoperitoneal (VP) shunting is the first-line treatment for hydrocephalus; however, when the peritoneal catheter becomes obstructed due to encapsulation, the procedure may need to be converted to a ventriculoatrial (VA) shunt, which serves as a second-line treatment.
View Article and Find Full Text PDFQuality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology.
Eur J Prev Cardiol
March 2025
Clinical Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Via Morandi 30, Milan 20097, Italy.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a range of physical and psychological symptoms, including shortness of breath, chest discomfort, fatigue, fluid congestion, trouble with sleeping, and depression. These symptoms reduce patients' capacity for daily social and physical activity.
View Article and Find Full Text PDFQuality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology.
Eur J Heart Fail
March 2025
Clinical Cardiology, IRCCS Policlinico San Donato, Milan, Italy.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a range of physical and psychological symptoms, including shortness of breath, chest discomfort, fatigue, fluid congestion, trouble with sleeping, and depression. These symptoms reduce patients' capacity for daily social and physical activity.
View Article and Find Full Text PDFMacitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.
Circ Heart Fail
March 2025
Department of Medicine, University of Maryland School of Medicine, Baltimore (M.T.G.).
Background: Despite favorable hemodynamic and neurohormonal effects, endothelin receptor antagonists have not improved outcomes in patients with heart failure (HF), possibly because they cause fluid retention.
Methods: In this randomized, double-blind, multicenter trial (SERENADE [Macitentan in Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease]), we evaluated the effects of an endothelin receptor antagonist, macitentan, in patients with HF, left ventricular ejection fraction ≥40%, and pulmonary vascular disease. After a 4-week placebo run-in (to ensure clinical stability), followed by a 5-week single-blind macitentan run-in, patients who did not exhibit fluid retention were randomized to macitentan or placebo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!